Thomas Olson
Directeur des opérations chez Acesis BioMed US, Inc.
Postes actifs de Thomas Olson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Acesis BioMed US, Inc.
 Acesis BioMed US, Inc. Pharmaceuticals: MajorHealth Technology IASO BioMed, Inc. operates as a developmental stage biotechnology company. It focuses on researching and developing a drug. The company founded on March 11, 2015 and is headquartered in Centennial, CO. | Directeur des opérations | - | - |
Acesis Holdings Corp.
 Acesis Holdings Corp. BiotechnologyHealth Technology Acesis Holdings Corp. functions as an investment holding company whose subsidiaries developing platform of oral drug candidates for metabolic and endocrine disorders. The company was founded on October 3, 2022 and is headquartered in Lone Tree, CO. | Directeur des opérations | 03/10/2022 | - |
| Secrétaire Général | 03/10/2022 | - | |
| Cresthill Associates, LLC | Corporate Officer/Principal | - | - |
Historique de carrière de Thomas Olson
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Chief Operating Officer | 2 |
| Corporate Secretary | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Acesis BioMed US, Inc.
Acesis BioMed US, Inc. Pharmaceuticals: MajorHealth Technology IASO BioMed, Inc. operates as a developmental stage biotechnology company. It focuses on researching and developing a drug. The company founded on March 11, 2015 and is headquartered in Centennial, CO. | Health Technology |
Acesis Holdings Corp.
Acesis Holdings Corp. BiotechnologyHealth Technology Acesis Holdings Corp. functions as an investment holding company whose subsidiaries developing platform of oral drug candidates for metabolic and endocrine disorders. The company was founded on October 3, 2022 and is headquartered in Lone Tree, CO. | Health Technology |
| Cresthill Associates, LLC |
- Bourse
- Insiders
- Thomas Olson
- Expérience
